Aromatase inhibitors (AIs) have emerged as a vital component of this therapeutic approach, offering a survival advantage by inhibiting the enzyme aromatase, thereby reducing estrogen levels and inhibiting the growth of breast cancer cells [6]. Here, CYP19A1 is linked to breast carcinoma.